Skip to content

Expanded Access to ABBV-8E12

Expanded Access to ABBV-8E12

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT03744546
Enrollment
Unknown
Registered
2018-11-16
Start date
Unknown
Completion date
Unknown
Last updated
2019-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Tauopathy Corticobasal Degeneration Syndrome (CBD)

Keywords

Expanded Access, Pre-approval Access, Compassionate Use, Special Access Program, Named Patient Basis, Special Access Scheme.

Brief summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABBV-8E12 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Interventions

Solution for infusion

Sponsors

AbbVie
Lead SponsorINDUSTRY

Eligibility

Age
40 Years to No maximum
Healthy volunteers
No

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026